Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study
ConclusionsNearly all patients reported side effects of ICMs at least 1 year after starting treatment. Our findings suggest that ICM side effect screening and management—especially for aching joints and fatigue—are indicated during long-term care of people living with advanced melanoma.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Graduation | Melanoma | Skin | Skin Cancer | Statistics | Study | Thyroid | Thyroid Cancer